drugset
Drugs / γ-globin reactivated autologous hematopoietic stem cells
last change Nov 2023 re-read 3 minutes ago

γ-globin reactivated autologous hematopoietic stem cells

Cell therapy targets BCL11A via restoration

Developed for
beta-thalassemia major
Investigated by
Bioray Laboratories · The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army · Xiangya Hospital of Central South University

Trials 1

today NCT04211480 · not/applicable
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT04211480 Oct 2020 → Oct 2023 beta-thalassemia major Bioray Laboratories Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as γ-globin reactivated autologous hematopoietic stem cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04211480 ↗
Action Restore “γ-globin reactivated autologous hematopoietic stem cells” NCT04211480 ↗
Modality Cell therapy “gene edited autologous hematopoietic stem cells with γ-globin expression” NCT04211480 ↗
Target BCL11A “Gene editing to disrupt the GATA1-binding site at the +58 BCL11A erythroid enhancer could induce γ-globin expression” PMID 35922667 ↗ Aug 2022